enkephalin: the endogenous opioid pentapeptides explained

enkephalin is a pair of five-amino-acid peptides, Met-enkephalin (YGGFM) and Leu-enkephalin (YGGFL), that the body uses as native opioid signals. they prefer the delta opioid receptor (DOR), break down in seconds, and were the first endogenous opioids ever identified. they have no FDA-approved use but are central tools in opioid pharmacology research.

what is enkephalin?

enkephalins are short opioid peptides produced from a precursor protein called proenkephalin and released by neurons and adrenal medulla cells. the two forms differ only at position five: methionine in Met-enkephalin, leucine in Leu-enkephalin.

the discovery story is one of the cleanest in peptide biology. in 1975 John Hughes, Hans Kosterlitz, and colleagues at the University of Aberdeen isolated two pentapeptides from pig brain that bound the same receptor as morphine, named them enkephalins, and published the sequences in Nature [1]. the finding answered a question that had hung over neuroscience for years: if the brain has opioid receptors, what is the brain making to bind them?

both enkephalins share the N-terminal motif Tyr-Gly-Gly-Phe, which is the same opening sequence found in endorphins and dynorphins. that motif is the "opioid signature" and is what lets all three families dock into opioid receptors. the C-terminal residue determines receptor selectivity, half-life, and the tissue distribution of the parent precursor protein.

how do they signal?

enkephalin binds opioid receptors, which are G-protein-coupled receptors that inhibit neuronal firing. enkephalin shows preferential affinity for the delta opioid receptor (DOR) and weaker affinity for the mu opioid receptor (MOR), the opposite of morphine's profile.

once enkephalin docks into DOR or MOR, the receptor activates inhibitory G proteins (Gi/Go). this lowers cyclic AMP, closes voltage-gated calcium channels at presynaptic terminals, and opens potassium channels at postsynaptic membranes. the net effect is to silence the neuron: less transmitter released into the synapse, less excitation downstream [2]. that inhibitory pattern is the cellular basis for opioid analgesia, but it also explains why the system regulates mood, autonomic tone, reward, and gut motility.

DOR-selective signaling is a distinct pharmacology from MOR-selective signaling. DOR agonism in preclinical work is associated with anxiolytic and antidepressant-like effects with less respiratory depression and less classic euphoria than MOR agonism, which is one reason DOR has been a target of interest for non-addictive analgesic research [3]. the trade-off is that DOR-selective agonists in earlier animal work also produced seizures at high exposure, a finding that shaped how modern DOR ligands are screened.

why doesn't native enkephalin work as a drug?

native enkephalin is destroyed within seconds in plasma by two peptidases, and it does not cross the blood-brain barrier. that pharmacokinetic wall is the reason no enkephalin drug exists despite fifty years of interest.

two enzymes do most of the damage. aminopeptidase N cleaves the N-terminal tyrosine and abolishes opioid activity, and neutral endopeptidase (neprilysin, NEP) cleaves the Gly-Phe bond and finishes the job [4]. give native enkephalin systemically and most of it is gone before it reaches a receptor. on top of that, the molecule is too polar to passively cross the blood-brain barrier, so even the surviving fraction stays mostly in the periphery.

two design strategies have been pursued to get around the wall. the first is structural: build peptide analogs that resist peptidase cleavage and cross the blood-brain barrier better. DADLE ([D-Ala2, D-Leu5]-enkephalin), DAMGO ([D-Ala2, MePhe4, Gly-ol5]-enkephalin), and DPDPE ([D-Pen2, D-Pen5]-enkephalin) are three workhorse research analogs built this way, each with different MOR/DOR selectivity [5]. biphalin, a dimeric analog from the Lipkowski group, is another well-studied scaffold. none are approved drugs; they are pharmacology tools.

the second strategy is to raise the level of native enkephalin instead of administering it directly. racecadotril (acetorphan) is an oral prodrug that inhibits neprilysin and protects endogenous enkephalin from degradation in the gut wall. it is approved as an antidiarrheal agent in many European, Asian, and Latin American markets and is one of the few enkephalin-system drugs that ever reached clinical use, although it is not FDA-approved in the US [6]. a related class of dual aminopeptidase-N and neprilysin inhibitors has been in preclinical analgesic research for decades.

where it fits in the broader peptide landscape

enkephalin is foundational to the endogenous opioid story but is not a consumer peptide. its lessons matter more than its use: it taught the field how to build peptidase-resistant analogs, how to think about receptor subtype selectivity, and how short circulating half-lives can be engineered around with careful chemistry.

for context, the endogenous opioid system has three main peptide families. enkephalins, from proenkephalin, prefer DOR. beta-endorphin and the rest of the endorphin family, from proopiomelanocortin (POMC), prefer MOR. dynorphins, from prodynorphin, prefer the kappa opioid receptor (KOR). all three share the YGGF opioid motif, which is one of the more elegant examples of how a single short sequence anchors a whole signaling family.

on the receptor side, MOR, DOR, and KOR are all Gi-coupled GPCRs, and the field has spent decades trying to dissociate analgesia from respiratory depression, tolerance, and reward. DOR-selective enkephalin analogs were one of the earliest tries at that separation and remain a teaching example of why selectivity matters more than potency. the lessons here generalize to other short-peptide families with rapid clearance, including DSIP and the Khavinson bioregulators, where the same questions about bioavailability and target validation apply.

enkephalin is also a useful counter-example for people new to the peptide space. an endogenous peptide with a well-defined receptor and a half-century of research is still not a clinical drug, because pharmacokinetics killed it. that should sharpen the question anyone asks of a newer compound: not "does it bind?" but "does it survive in the body long enough to reach the receptor it is supposed to bind?"

safety, status, and honest framing

there is no FDA-approved enkephalin or enkephalin-analog drug. native enkephalin and its analogs are research tools, used in animal pharmacology and in vitro work. anything sold as enkephalin to consumers is outside any regulatory pathway and carries unknown identity, purity, and biological activity.

the safety profile of native enkephalin in humans is essentially undefined as a chronic exposure, because the molecule has never been developed as a chronic medicine. what is known is that opioid receptors broadly mediate respiratory depression, tolerance, dependence, constipation, and reward effects when chronically engaged, and any compound that activates them at scale inherits that risk. the DOR-selectivity of enkephalin reduces but does not eliminate that family of concerns.

from a regulatory standpoint, the absence of an approved enkephalin product means there is no labeled indication, no FDA-reviewed manufacturing standard, and no formal safety follow-up. the closest the system has come to a real-world drug is racecadotril, which raises endogenous enkephalin in the gut and is used for acute diarrhea outside the US. for everything else, this is a research topic, not a product category.